|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.3 CHF | +0.12% |
|
-1.10% | +14.16% |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
| Apr. 04 | Stocks Close in Green as Swiss Inflation Unexpectedly Slows | MT |
Basilea Pharmaceutica AG reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was CHF 148.12 million compared to CHF 127.63 million a year ago. Net loss was CHF 6.83 million compared to CHF 14.72 million a year ago.
Basic loss per share from continuing operations was CHF 0.58 compared to CHF 1.43 a year ago. Diluted loss per share from continuing operations was CHF 0.58 compared to CHF 1.43 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +14.16% | 529M | |
| +2.08% | 42.59B | |
| +8.14% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.84% | 24.81B | |
| -24.34% | 18.17B | |
| +28.71% | 12.05B | |
| -2.72% | 11.7B | |
| +6.89% | 11.1B |
BASILEA PHARMACEUTICA AG 
